Skip to main content
SpringerLink
Log in
Book cover

Encyclopedia of Signaling Molecules pp 5818–5823Cite as

Ubiquitin Carboxyl-Terminal Hydrolase CYLD

  • Reference work entry
  • First Online:

  • 127 Accesses

Synonyms

CYLD; CYLD lysine 63 deubiquitinase; Cylindromatosis (turban tumor syndrome); Deubiquitinating enzyme CYLD; Probable ubiquitin carboxyl-terminal hydrolase CYLD; Ubiquitin-specific peptidase-like 2; Ubiquitin thioesterase CYLD; Ubiquitin-specific-processing protease CYLD

Historical Background

CYLD is a deubiquitination enzyme that is responsible for cleaving polyubiquitin chains from multiple target proteins and for regulating downstream signaling pathways. Originally, CYLD gene was discovered through positional cloning from chromosome 16q. The germ-line mutations in CYLD gene were identified in patients suffering from familial cylindromatosis, which is a skin cancer disease (Biggs et al. 1995; Bignell et al. 2000). Both copies of the gene must be inactivated to cause cylindromatosis, which is usually an inherited mutation in one copy and loss of the second copy during postnatal life. CYLD consists of 956 amino acids, 20 exons, and it is scattered over 56 kb of genomic DNA...

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   4,499.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   4,499.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  • An J, Mo D, Liu H, Veena MS, Srivatsan ES, Massoumi R, et al. Inactivation of the CYLD deubiquitinase by HPV E6 mediates hypoxia-induced NF-kappa B activation. Cancer Cell. 2008;14(5):394–407.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Biggs PJ, Wooster R, Ford D, Chapman P, Mangion J, Quirk Y, et al. Familial cylindromatosis (Turban tumor syndrome) gene localized to chromosome 16Q12-Q13 – evidence for its role as a tumor-suppressor gene. Nat Genet. 1995;11(4):441–3.

    Article  PubMed  CAS  Google Scholar 

  • Bignell GR, Warren W, Seal S, Takahashi M, Rapley E, Barfoot R, et al. Identification of the familial cylindromatosis tumour-suppressor gene. Nat Genet. 2000;25(2):160–5.

    Article  PubMed  CAS  Google Scholar 

  • Hellerbrand C, Massoumi R. Cylindromatosis – a protective molecule against liver diseases. Med Res Rev. 2016;36(2):342–59.

    Article  PubMed  CAS  Google Scholar 

  • Hutti JE, Shen RR, Abbott DW, Zhou AY, Sprott KM, Asara JM, et al. Phosphorylation of the tumor suppressor CYLD by the breast cancer oncogene IKK epsilon promotes cell transformation. Mol Cell. 2009;34(4):461–72.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Kikuno N, Shiina H, Urakami S, Kawamoto K, Hirata H, Tanaka Y, et al. Genistein mediated histone acetylation and demethylation activates tumor suppressor genes in prostate cancer cells. Int J Cancer. 2008;123(3):552–60.

    Article  PubMed  CAS  Google Scholar 

  • Komander D, Lord CJ, Scheel H, Swift S, Hofmann K, Ashworth A, et al. The structure of the CYLD USP domain explains its specificity for Lys63-linked polyubiquitin and reveals a B box module. Mol Cell. 2008;29(4):451–64.

    Article  PubMed  CAS  Google Scholar 

  • Kuphal S, Shaw-Hallgren G, Eberl M, Karrer S, Aberger F, Bosserhoff AK, et al. GLI1-dependent transcriptional repression of CYLD in basal cell carcinoma. Oncogene. 2011;30(44):4523–30.

    Article  PubMed  CAS  Google Scholar 

  • Massoumi R. Ubiquitin chain cleavage: CYLD at work. Trends Biochem Sci. 2010;35(7):392–9.

    Article  PubMed  CAS  Google Scholar 

  • Massoumi R. CYLD: a deubiquitination enzyme with multiple roles in cancer. Future Oncol. 2011;7(2):285–97.

    Article  PubMed  CAS  Google Scholar 

  • Massoumi R, Chmielarska K, Hennecke K, Pfeifer A, Fassler R. Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-kappa B signaling. Cell. 2006;125(4):665–77.

    Article  PubMed  CAS  Google Scholar 

  • Massoumi R, Kuphal S, Hellerbrand C, Haas B, Wild P, Spruss T, et al. Down-regulation of CYLD expression by Snail promotes tumor progression in malignant melanoma. J Exp Med. 2009;206(1):221–32.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Pickart CM. Mechanisms underlying ubiquitination. Annu Rev Biochem. 2001;70:503–33.

    Article  PubMed  CAS  Google Scholar 

  • Strobel P, Zettl A, Ren Z, Starostik P, Riedmiller H, Storkel S, et al. Spiradenocylindroma of the kidney: clinical and genetic findings suggesting a role of somatic mutation of the CYLD1 gene in the oncogenesis of an unusual renal neoplasm. Am J Surg Pathol. 2002;26(1):119–24.

    Article  PubMed  Google Scholar 

  • Tauriello DV, Haegebarth A, Kuper I, Edelmann MJ, Henraat M, Canninga-van Dijk MR, et al. Loss of the tumor suppressor CYLD enhances Wnt/beta-catenin signaling through K63-linked ubiquitination of Dvl. Mol Cell. 2010;37(5):607–19.

    Article  PubMed  CAS  Google Scholar 

  • Trompouki E, Tsagaratou A, Kosmidis SK, Dolle P, Qian J, Kontoyiannis DL, et al. Truncation of the catalytic domain of the cylindromatosis tumor suppressor impairs lung maturation. Neoplasia. 2009;11(5):469–76.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Weissman AM. Themes and variations on ubiquitylation. Nat Rev Mol Cell Biol. 2001;2(3):169–78.

    Article  PubMed  CAS  Google Scholar 

  • Wickstrom SA, Masoumi KC, Khochbin S, Fassler R, Massoumi R. CYLD negatively regulates cell-cycle progression by inactivating HDAC6 and increasing the levels of acetylated tubulin. EMBO J. 2010;29(1):131–44.

    Article  PubMed  CAS  Google Scholar 

  • Zhang J, Stirling B, Temmerman ST, Ma CA, Fuss IJ, Derry JMJ, et al. Impaired regulation of NF-kappa B and increased susceptibility to colitis-associated tumorigenesis in CYLD-deficient mice. J Clin Investig. 2006;116(11):3042–9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Zhong S, Fields CR, Su N, Pan YX, Robertson KD. Pharmacologic inhibition of epigenetic modi. cations, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer. Oncogene. 2007;26(18):2621–34.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Laboratory Medicine, Molecular Tumor Pathology, Translational Cancer Research, Lund University, Scheelevägen 8, Medicon Village, 22381, Lund, Sweden

    Ramin Massoumi & Hengning Ke

Authors
  1. Ramin Massoumi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hengning Ke
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ramin Massoumi .

Editor information

Editors and Affiliations

  1. Department of Molecular Science and Technology, Ajou University, Suwon, Korea

    Sangdun Choi

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Massoumi, R., Ke, H. (2018). Ubiquitin Carboxyl-Terminal Hydrolase CYLD. In: Choi, S. (eds) Encyclopedia of Signaling Molecules. Springer, Cham. https://doi.org/10.1007/978-3-319-67199-4_101927

Download citation

Publish with us

Policies and ethics

Search

Navigation